ANNAPOLIS – Biodefense firm PharmAthene, Inc. last week presented overall positive findings from the federally funded Phase II research on SparVax and Valortim, its two potentially promising vaccines for civilian defense against anthrax infection. Presented at the 7th Annual Biodefense Meeting of the American Society of Microbiology, the research evaluated the safety, tolerability and immunogenic capability of the compounds.
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1323698127.gif)
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1270748889.png)
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1286484661.jpg)
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1312923369.jpg)
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1313587373.gif)
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1268857522.jpg)
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1270748904.png)
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1286484732.jpg)